Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr 8:21:22.
doi: 10.4103/1735-1995.179890. eCollection 2016.

Meta-analysis of studies comparing adjuvant dexamethasone to glycerol to improve clinical outcome of bacterial meningitis

Siavash Vaziri  1 , Fiezollah Mansouri  1 , Babak Sayad  1 , Keyghobad Ghadiri  1 , Elham Torkashvand  1 , Mansour Rezaei  2 , Farid Najafi  2 , Mohsen Azizi  3
Affiliations
Review

Meta-analysis of studies comparing adjuvant dexamethasone to glycerol to improve clinical outcome of bacterial meningitis

Siavash Vaziri et al. J Res Med Sci. .

Abstract

Background: Neurological complications are a problematic factor in acute bacterial meningitis; hence, its prevention is the key to ensure the success of meningitis treatment. Glycerol and dexamethasone are both applied in this regard. Oral glycerol is an appropriate alternative instead of intravenous dexamethasone because it does not have problems related to intravenous injection, the high cost, and drug complications. The main objective of this study was to compare the efficacy of adjuvant dexamethasone versus glycerol in order to improve the clinical outcome of bacterial meningitis.

Materials and methods: We conducted a search on the available resources including PubMed, Ovid, Elsevier, Cochrane, and another search engines such as Google till 2014. All clinical trials that were performed in the field of comparing the effectiveness of the two drugs and met the inclusion criteria were gathered and after extraction the relative risk (RR) values, the pooled RR was calculated. The main outcome was neurological complications. Meta-analysis of the data was performed in Stata version 11.2 using both fixed and random effect models, weighting each study by inverse of variance.

Results: In 5 comparative studies (1,340 patients), the rate of neurological complications of glycerol compared to that of dexamethasone was 1.02 [95% confidence interval (CI), 0.98 compared to 1.12]. The rate of neurological complications of dexamethasone compared to dexamethasone + glycerol was 1 (95% CI, 0.97 compared to 1.03), dexamethasone compared to placebo was 0.99 (95% CI, 0.97 compared to 1.03), glycerol compared to glycerol + dexamethasone was 0.98 (95% CI, 0.94 compared to 1.02), and glycerol compared to placebo was 0.97 (95% CI, 0.94 compared to 1.01). In these studies, no difference was reported between dexamethasone and glycerol in terms of reducing neurological complications.

Conclusion: Although there were some weak evidences for the nonstatistical significant effect of glycerol in the prevention of neurologic complication after meningitis, there was no difference between glycerol and dexamethasone.

Keywords: Dexamethasone; glycerol; meningitis; neurological complications.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram for study selection
Figure 2
Figure 2
The comparison of dexamethasone with glycerol based on the random effect model
Figure 3
Figure 3
Funnel plot with pseudo 95% confidence limits by event rate
Figure 4
Figure 4
The comparison of dexamethasone with dexamethasone + glycerol based on the random effect model
Figure 5
Figure 5
The comparison of dexamethasone with placebo based on the random effect model
Figure 6
Figure 6
The comparison of glycerol with glycerol + dexamethasone based on the random effect model
Figure 7
Figure 7
The comparison of glycerol with placebo based on the random effect model
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med. 2006;354:44–53. - PubMed
    1. Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: A meta-analysis. Pediatr Infect Dis J. 1993;12:389–94. - PubMed
    1. Koomen I, Grobbee DE, Roord JJ, Donders R, Jennekens-Schinkel A, van Furth AM. Hearing loss at school age in survivors of bacterial meningitis: Assessment, incidence, and prediction. Pediatrics. 2003;112:1049–53. - PubMed
    1. Richardson MP, Reid A, Tarlow MJ, Rudd PT. Hearing loss during bacterial meningitis. Arch Dis Child. 1997;76:134–8. - PMC - PubMed
    1. Grimwood K, Anderson P, Anderson V, Tan L, Nolan T. Twelve year outcomes following bacterial meningitis: Further evidence for persisting effects. Arch Dis Child. 2000;83:111–6. - PMC - PubMed